Marie Cullberg
Overview
Explore the profile of Marie Cullberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandez-Teruel C, Cullberg M, Eberlein C, Barry S, Zhou D
Clin Pharmacokinet
. 2024 Aug;
63(8):1191-1204.
PMID: 39127854
Background And Objective: Overactivation of the PI3K/AKT pathway can occur in many cancers. Capivasertib is a potent, selective pan-AKT inhibitor. The objectives of this analysis were to develop a population...
2.
Miller C, Wild M, Zhang Z, Sommavilla R, Shanahan D, Bailey C, et al.
Drug Metab Dispos
. 2024 Jul;
52(9):939-948.
PMID: 39029948
An open-label, single-center, phase I study was conducted to determine the absolute bioavailability and absorption, distribution, metabolism, and excretion of capivasertib-a potent, selective AKT serine/threonine kinase inhibitor-in healthy males. In...
3.
Miller C, Sommavilla R, OBryant C, Barve M, Dowlati A, Luke J, et al.
Cancer Chemother Pharmacol
. 2024 Apr;
94(2):223-235.
PMID: 38643311
Purpose: Capivasertib, a potent, selective inhibitor of all three AKT serine/threonine kinase (AKT) isoforms, is being evaluated in phase 3 trials in advanced breast and prostate cancer. This study evaluated...
4.
Miller C, Sommavilla R, Barry S, Eberlein C, Morris T, Wadsworth I, et al.
Clin Pharmacol Drug Dev
. 2023 Jul;
12(9):856-862.
PMID: 37449963
Capivasertib is a potent, selective inhibitor of all 3 Akt isoforms (Akt1/2/3), and it is currently being tested in Phase III trials for the treatment of prostate and breast cancer....
5.
Miller C, Sommavilla R, Murphy D, Morris T, Khatun M, Cullberg M
Br J Clin Pharmacol
. 2023 Jun;
89(11):3330-3339.
PMID: 37328269
Aims: This two-part, adaptive study assessed the effect of food and an acid-reducing agent (rabeprazole) on the pharmacokinetics (PK) and safety of capivasertib, a potent AKT inhibitor, in clinical development...
6.
Shore N, Mellado B, Shah S, Hauke R, Costin D, Adra N, et al.
Clin Genitourin Cancer
. 2022 Dec;
21(2):278-285.
PMID: 36572571
Background: Although androgen receptor-targeted agents prolong the lives of patients with metastatic prostate cancer, patients develop therapy resistance and most ultimately succumb to the disease. The PI3K/AKT/PTEN pathway has been...
7.
Robertson J, Coleman R, Cheung K, Evans A, Holcombe C, Skene A, et al.
Clin Cancer Res
. 2022 Dec;
28(24):5469.
PMID: 36519303
No abstract available.
8.
Voronova V, Cullberg M, Delff P, Parkinson J, Dota C, Schiavon G, et al.
Br J Clin Pharmacol
. 2021 Jul;
88(2):858-864.
PMID: 34309049
Pharmacokinetics-matched digital electrocardiogram data (n = 503 measurements from 180 patients) collected in a first-in-human, multi-part, dose-escalation (from 80 to 800 mg) and dose expansion (at 480 mg) phase 1...
9.
Robertson J, Coleman R, Cheung K, Evans A, Holcombe C, Skene A, et al.
Clin Cancer Res
. 2019 Dec;
26(7):1574-1585.
PMID: 31836609
Purpose: The STAKT study examined short-term exposure (4.5 days) to the oral selective pan-AKT inhibitor capivasertib (AZD5363) to determine if this drug can reach its therapeutic target in sufficient concentration...
10.
Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wahlby Hamren U, et al.
Drugs R D
. 2018 Jun;
18(2):149-159.
PMID: 29856004
Objective: The aim of this study was to summarise the pharmacokinetic findings from eight phase I studies in healthy volunteers given oral AZD5069, a selective small-molecule CXCR2 antagonist. Methods: 240...